

CITATION REPORT

List of articles citing

Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis

DOI: 10.1016/j.jash.2014.01.007

Journal of the American Society of Hypertension, 2014, 8, 262-75.e9.

Source: <https://exaly.com/paper-pdf/58921368/citation-report.pdf>

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
336	Efficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozin. 2014 , 4, e143		73
335	[Hypertension and diabetes: target blood pressure and blood pressure lowering by new antidiabetic drugs]. 2014 , 139, 2468-9		1
334	Dapagliflozin for the treatment of Type 2 diabetes. 2014 , 9, 435-443		
333	Sodium glucose transporter protein 2 inhibitors: focusing on the kidney to treat type 2 diabetes. 2014 , 5, 124-36		24
332	Empagliflozin for the treatment of type 2 diabetes. 2014 , 15, 2429-41		10
331	The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system. 2014 , 11, 306-23		40
330	Antihypertensive treatments in obese patients: the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial experience. 2014 , 32, 1402-4		
329	Blood pressure effects of glucagon-like peptide 1 analogues and sodium glucose transporter 2 inhibitors. <i>Current Opinion in Nephrology and Hypertension</i> , 2014 , 23, 468-72	3.5	3
328	Place of sodium-glucose co-transporter type 2 inhibitors for treatment of type 2 diabetes. 2014 , 5, 854-9		30
327	Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. <i>Journal of the American Society of Hypertension</i> , 2014 , 8, 262-75.e9		296
326	Evaluating cardiovascular safety of novel therapeutic agents for the treatment of type 2 diabetes mellitus. 2014 , 16, 541		13
325	Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis. 2014 , 16, 984-93		146
324	Canagliflozin: a review of its use in patients with type 2 diabetes mellitus. 2014 , 74, 807-24		50
323	Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial. <i>Cardiovascular Diabetology</i> , 2015 , 14, 154	8.7	74
322	Comparative efficacy and safety of antidiabetic drug regimens added to stable and inadequate metformin and thiazolidinedione therapy in type 2 diabetes. 2015 , 69, 1221-35		15
321	The potential role of sodium glucose co-transporter 2 inhibitors in the early treatment of type 2 diabetes mellitus. 2015 , 69, 1071-87		22
320	Management of Diabetes Associated with Nephrotic Syndrome: Therapeutic Potential of Dapagliflozin for Protracted Volume Retention. 2015 , 9, 29-31		6

319	Sodium-glucose cotransporter-2 inhibitors and blood pressure decrease: a valuable effect of a novel antidiabetic class?. 2015 , 33, 2185-97		43
318	Empagliflozin as add-on to metformin in people with Type 2 diabetes. 2015 , 32, 1555-67		58
317	Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. 2015 , 17, 1180-93		289
316	Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus. <i>Cardiovascular Diabetology</i> , 2015 , 14, 142	8.7	55
315	Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes. 2015 , 38, 394-402		146
314	Sodium-glucose cotransporter 2 inhibitors and renal function-2. 2015 , 7, 295-8		5
313	Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. 2015 , 38, 384-93		210
312	Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study. <i>Cardiovascular Diabetology</i> , 2015 , 14, 11	8.7	79
311	SGLT-2 Inhibitors: Potential Novel Strategy to Prevent Congestive Heart Failure in Diabetes?. 2015 , 9, 1		6
310	The Use of SGLT-2 Inhibitors in Type 2 Diabetes and Heart Failure. 2015 , 13, 292-7		12
309	Inhibiteurs du SGLT2 : m�canisme d'action, effets r�aux et effets sur la pression art�rielle. 2015 , 9, S26-S29		2
308	Are SGLT2 inhibitors reasonable antihypertensive drugs and renoprotective?. <i>Current Hypertension Reports</i> , 2015 , 17, 551	4.7	20
307	Efficacy and safety of empagliflozin monotherapy for 52 weeks in Japanese patients with type 2 diabetes: a randomized, double-blind, parallel-group study. 2015 , 32, 306-18		35
306	Canagliflozin for Type 2 diabetes: an up-to-date evidence summary. 2015 , 5, 119-125		2
305	Comparative efficacy and safety of antidiabetic drug regimens added to metformin monotherapy in patients with type 2 diabetes: a network meta-analysis. 2015 , 10, e0125879		98
304	Update on long-term efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitus. 2015 , 6, 61-7		24
303	Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. 2015 , 38, 420-8		291
302	Single-pill combination therapy for type 2 diabetes mellitus: linagliptin plus empagliflozin. 2015 , 31, 901-11		9

301	Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of randomized controlled trials for 1 to 2years. 2015 , 29, 1295-303	92
300	RSSDI Clinical Practice Recommendations for Management of Type 2 Diabetes Mellitus, 2015. 2015 , 35, 1-71	9
299	SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment. 2015 , 14, 1879-904	49
298	Sodium glucose co-transporter inhibitors for the management of diabetes mellitus: an opinion paper from the Endocrine and Metabolism Practice and Research Network of the American College of Clinical Pharmacy. 2015 , 31, 1733-41	3
297	Remogliflozin etabonate: a novel SGLT2 inhibitor for treatment of diabetes mellitus. 2015 , 24, 1381-7	14
296	Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus. 2015 , 32, 768-82	28
295	Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. 2015 , 75, 33-59	311
294	SGLT2 inhibitors: their potential reduction in blood pressure. <i>Journal of the American Society of Hypertension</i> , 2015 , 9, 48-53	65
293	The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus. 2015 , 66, 255-70	177
292	A Case of Isolated Glycosuria Mediated by an Gene Mutation and Characterized by Postprandial Heavy Glycosuria Without Salt Wasting. 2016 , 14, 35-37	3
291	Changes in HbA1c, body weight, and systolic blood pressure in type 2 diabetes patients initiating dapagliflozin therapy: a primary care database study. 2016 , 9, 337-345	15
290	Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure. 2016 , 12, 393-405	38
289	Options for empagliflozin in combination therapy in type 2 diabetes mellitus. 2016 , 9, 155-72	12
288	Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. 2016 , 11, e0166125	126
287	Potential role of sodium glucose cotransporter 2 inhibitors in the treatment of hypertension. <i>Current Opinion in Nephrology and Hypertension</i> , 2016 , 25, 81-6	3.5 26
286	Effects of dipeptidyl peptidase-4 inhibitors on blood pressure in patients with type 2 diabetes: A systematic review and meta-analysis. 2016 , 34, 167-75	41
285	Effects of diuretics on sodium-dependent glucose cotransporter 2 inhibitor-induced changes in blood pressure in obese rats suffering from the metabolic syndrome. 2016 , 34, 893-906	36
284	Update in Hypertension Therapy. 2016 , 100, 665-93	6

283	NUEVOS FARMACOS EN DIABETES MELLITUS. 2016 , 27, 235-256		2
282	Diabetes mellitus and hypertension: a dual threat. 2016 , 31, 402-9		23
281	New strategies to tackle diabetic kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2016 , 25, 348-54	3.5	2
280	Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus. 2016 , 37, 3192-3200		117
279	Pharmacodynamic Effects of Single and Multiple Doses of Empagliflozin in Patients With Type 2 Diabetes. 2016 , 38, 2265-2276		53
278	Acute Pharmacodynamic Effects of Empagliflozin With and Without Diuretic Agents in Patients With Type 2 Diabetes Mellitus. 2016 , 38, 2248-2264.e5		33
277	Effects of reducing blood pressure on cardiovascular outcomes and mortality in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME. 2016 , 121, 204-214		33
276	Sodium glucose co-transporter 2 inhibitors in patients with resistant hypertension: a case study. 2016 , 7, 2054270416649285		3
275	Initial Combination of Empagliflozin and Metformin in Patients With Type 2 Diabetes. 2016 , 39, 1718-28		56
274	Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications. <i>Circulation</i> , 2016 , 134, 752-72	16.7	631
273	Efficacy, safety, and tolerability of ipragliflozin in Asian patients with type 2 diabetes mellitus and inadequate glycemic control with metformin: Results of a phase 3 randomized, placebo-controlled, double-blind, multicenter trial. 2016 , 7, 366-73		45
272	Reductions in Mean 24-Hour Ambulatory Blood Pressure After 6-Week Treatment With Canagliflozin in Patients With Type 2 Diabetes Mellitus and Hypertension. 2016 , 18, 43-52		59
271	Is it time to think about the sodium glucose co-transporter 2 sympathetically?. 2016 , 21, 286-94		17
270	SGLT2 Inhibitors: Benefit/Risk Balance. 2016 , 16, 92		64
269	Diuretic Action of Sodium-Glucose Cotransporter 2 Inhibitors and Its Importance in the Management of Heart Failure. 2016 , 80, 2277-2281		38
268	Cardiovascular effects of anti-diabetes drugs. 2016 , 15, 1239-57		11
267	SGLT2-Antagonisten kein Medikament gegen Diabetes und Bluthochdruck?. 2016 , 16, 42-44		
266	Reappraisal of the diuretic effect of empagliflozin in the EMPA-REG OUTCOME trial: Comparison with classic diuretics. 2016 , 42, 224-33		55

265	Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors. 2016 , 17, 1581-3		23
264	Importance of inhibiting sodium-glucose cotransporter and its compelling indication in type 2 diabetes: pathophysiological hypothesis. <i>Journal of the American Society of Hypertension</i> , 2016 , 10, 271-8		41
263	A Safety Evaluation of Empagliflozin for the Treatment of Type 2 Diabetes. 2016 , 15, 393-402		9
262	Cardiovascular safety of anti-diabetic drugs. 2016 , 2, 32-43		34
261	A Multifactorial Approach to Reduce Cardiovascular Disease in Type 2 Diabetes Mellitus: Now More Than Ever. 2016 , 44, 9-20		1
260	DPP-4 inhibitors and cardiovascular disease in type 2 diabetes mellitus. Expectations, observations and perspectives. 2016 , 26, 273-84		16
259	Cardiovascular outcomes of sodium-glucose cotransporter 2 inhibitors: A comprehensive review of clinical and preclinical studies. 2016 , 212, 29-36		38
258	Sodium-glucose cotransporter 2 inhibitors and cardiovascular outcomes. 2016 , 128, 398-408		2
257	Extra-glycaemic properties of empagliflozin. 2016 , 32, 230-7		5
256	Effect of ipragliflozin, an SGLT2 inhibitor, on progression of diabetic microvascular complications in spontaneously diabetic Torii fatty rats. <i>Life Sciences</i> , 2016 , 147, 125-31	6.8	25
255	Efficacy and safety of empagliflozin as add-on to metformin for type 2 diabetes: a systematic review and meta-analysis. 2016 , 72, 655-63		20
254	Hypertension: SGLT2 inhibitors: not just another glucose-lowering agent. 2016 , 12, 128-9		2
253	Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study. 2016 , 4, 211-220		143
252	Antihypertensive effects of SGLT2 inhibitors in type 2 diabetes. 2016 , 4, 188-189		26
251	Dapagliflozin combination therapy in type 2 diabetes mellitus. 2016 , 128, 124-36		2
250	Protective Role of Sodium-Glucose Co-Transporter 2 Inhibition Against Vascular Complications in Diabetes. 2016 , 19, 107-14		10
249	SGLT2 inhibitors. 2016 , 101, 27-39		19
248	Managing Diabetic Nephropathies in Clinical Practice: Emerging and Future Therapies. 2017 , 117-129		1

247	Blood pressure control in type 2 diabetic patients. <i>Cardiovascular Diabetology</i> , 2017 , 16, 3	8.7	44
246	Medical Management of Diabesity: Do We Have Realistic Targets?. 2017 , 17, 4		26
245	Effects of reducing blood pressure on renal outcomes in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME. 2017 , 43, 99-109		27
244	Cardiovascular safety of non-insulin pharmacotherapy for type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2017 , 16, 18	8.7	34
243	Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone. 2017 , 19, 721-728		95
242	Arterial pressure lability is improved by sodium-glucose cotransporter 2 inhibitor in streptozotocin-induced diabetic rats. 2017 , 40, 646-651		26
241	Effects of ipragliflozin, a selective sodium-glucose co-transporter 2 inhibitor, on blood pressure in Japanese patients with type 2 diabetes mellitus: a pooled analysis of six randomized, placebo-controlled clinical trials. 2017 , 8, 76-86		12
240	The efficacy and safety of SGLT2 inhibitors for adjunctive treatment of type 1 diabetes: a systematic review and meta-analysis. 2017 , 7, 44128		51
239	Sodium-glucose co-transporter-2 inhibitors and risk of adverse renal outcomes among patients with type 2 diabetes: A network and cumulative meta-analysis of randomized controlled trials. 2017 , 19, 1106-1115		49
238	Metabolic and hemodynamic effects of sodium-dependent glucose cotransporter 2 inhibitors on cardio-renal protection in the treatment of patients with type 2 diabetes mellitus. 2017 , 8, 416-427		31
237	Stroke paradox with SGLT-2 inhibitors: a play of chance or a viscosity-mediated reality?. 2017 , 88, 249-253		30
236	Dapagliflozin: potential beneficial effects in the prevention and treatment of renal and cardiovascular complications in patients with type 2 diabetes. 2017 , 18, 517-527		4
235	Mechanism of the blood pressure-lowering effect of sodium-glucose cotransporter 2 inhibitors in obese patients with type 2 diabetes. 2017 , 18, 23		49
234	The effects of intermittent use of the SGLT-2 inhibitor, dapagliflozin, in overweight patients with type 2 diabetes in Japan: a randomized, crossover, controlled clinical trial. 2017 , 18, 743-751		6
233	A Review of the Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitors: A Focus on Diabetic Ketoacidosis. 2017 , 30, 137-142		11
232	The Effect of Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibitors on Cardiometabolic Profile; Beyond the Hypoglycaemic Action. 2017 , 31, 215-225		7
231	Empagliflozin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Linagliptin and Metformin: A 24-Week Randomized, Double-Blind, Parallel-Group Trial. 2017 , 40, 201-209		77
230	Effects of Sodium-Glucose Cotransporter 2 Inhibitors on 24-Hour Ambulatory Blood Pressure: A Systematic Review and Meta-Analysis. 2017 , 6,		89

229	Do effects of sodium-glucose cotransporter-2 inhibitors in patients with diabetes give insight into potential use in non-diabetic kidney disease?. <i>Current Opinion in Nephrology and Hypertension</i> , 2017 , 26, 358-367	3.5	18
228	SGLT2-I in the Hospital Setting: Diabetic Ketoacidosis and Other Benefits and Concerns. 2017 , 17, 54		11
227	Effect of Sodium-Glucose Cotransport-2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of 43 Randomized Control Trials With 528 Patients. 2017 , 6,		158
226	Role of the sympathetic nervous system in regulation of the sodium glucose cotransporter 2. 2017 , 35, 2059-2068		97
225	SGLT2 inhibitor/DPP-4 inhibitor combination therapy - complementary mechanisms of action for management of type 2 diabetes mellitus. 2017 , 129, 409-420		25
224	Promise of SGLT2 Inhibitors in Heart Failure: Diabetes and Beyond. 2017 , 19, 23		58
223	Emerging roles of sodium-glucose cotransporter 2 inhibitors in cardiology. 2017 , 69, 501-507		22
222	Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials. <i>Circulation</i> , 2017 , 136, 1643-1658	16.7	256
221	The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors. 2017 , 19, 1390-1400		111
220	The effect of SGLT2 inhibitors on cardiovascular events and renal function. 2017 , 10, 1251-1261		9
219	Euglycemic ketoacidosis following a single dose of empagliflozin. 2017 , 1, 18-20		
218	Practical Approach to Initiating SGLT2 Inhibitors in Type 2 Diabetes. 2017 , 8, 953-962		25
217	The effect of empagliflozin on muscle sympathetic nerve activity in patients with type II diabetes mellitus. <i>Journal of the American Society of Hypertension</i> , 2017 , 11, 604-612		44
216	Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus. 2017 , 129, 811-821		32
215	Dapagliflozin slows the progression of the renal and liver fibrosis associated with type 2 diabetes. 2017 , 313, E563-E576		66
214	Sodium-glucose cotransporter-2 inhibitors: Expanding oral treatment options for type 2 diabetes mellitus. 2017 , 42, 8-15		1
213	Amelioration of arterial pressure lability: an unmissable target for diabetes management. 2017 , 40, 629-631		0
212	Dapagliflozin therapy for type 2 diabetes in primary care: Changes in HbA1c, weight and blood pressure over 2 years follow-up. 2017 , 11, 437-444		13

211	Effects of sodium-glucose co-transporter 2 inhibitors on metabolism: unanswered questions and controversies. 2017 , 13, 399-408		15
210	Impact of empagliflozin in patients with diabetes and heart failure. <i>Trends in Cardiovascular Medicine</i> , 2017 , 27, 144-151	6.9	12
209	Diabetes for Cardiologists: Practical Issues in Diagnosis and Management. 2017 , 33, 366-377		19
208	Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. 2017 , 60, 215-225		288
207	Addition of Ipragliflozin to Metformin Treatment in Korean Patients with Type 2 Diabetes Mellitus: Subgroup Analysis of a Phase 3 Trial. 2017 , 41, 135-145		14
206	SGLT2 Inhibitors as a Therapeutic Option for Diabetic Nephropathy. 2017 , 18,		93
205	Use of SGLT-2 inhibitors in the treatment of type 2 diabetes mellitus. 2017 , 63, 636-641		13
204	Differential cardiovascular profiles of sodium-glucose cotransporter 2 inhibitors: critical evaluation of empagliflozin. 2017 , 13, 603-611		5
203	Efficacy and Safety of SGLT2 Inhibitors in Reducing Glycated Hemoglobin and Weight in Emirati Patients With Type 2 Diabetes. 2017 , 9, 499-507		10
202	Editorial: Uncontrolled Hypertension and Related Comorbidities: A Clinician's Update. 2017 , 16, 3-4		
201	Does dapagliflozin regress left ventricular hypertrophy in patients with type 2 diabetes? A prospective, double-blind, randomised, placebo-controlled study. 2017 , 17, 229		18
200	Renoprotective Effects of SGLT2 Inhibitors: Beyond Glucose Reabsorption Inhibition. 2017 , 15, 96-102		18
199	Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date. 2017 , 11, 2905-2919		36
198	Antidiabetic Drugs as Antihypertensives: New Data on the Horizon. 2017 , 16, 70-78		3
197	An evidence-based practice-oriented review focusing on canagliflozin in the management of type 2 diabetes. 2017 , 13, 43-54		5
196	Cardiovascular benefits of the newer medications for treating type 2 diabetes mellitus. 2017 , 9, 2124-2134		19
195	RSSDI clinical practice recommendations for the management of type 2 diabetes mellitus 2017. 2018 , 38, 1-115		57
194	Comprehensive renoprotective effects of ipragliflozin on early diabetic nephropathy in mice. 2018 , 8, 4029		36

193	2018 consensus of the Taiwan Society of Cardiology and the Diabetes Association of Republic of China (Taiwan) on the pharmacological management of patients with type 2 diabetes and cardiovascular diseases. 2018 , 81, 189-222		14
192	Use and effectiveness of dapagliflozin in routine clinical practice: An Italian multicentre retrospective study. 2018 , 20, 1781-1786		25
191	A comparative safety review between GLP-1 receptor agonists and SGLT2 inhibitors for diabetes treatment. 2018 , 17, 293-302		22
190	Clinical impact of oral antidiabetic medications in heart failure patients. 2018 , 23, 325-335		7
189	Safety and efficacy of sodium-glucose cotransporter 2 (SGLT2) inhibitors in type 1 diabetes: A systematic review and meta-analysis. 2018 , 137, 83-92		27
188	Cardiovascular outcomes in diabetic kidney disease: insights from recent clinical trials. 2018 , 8, 8-17		6
187	Cardioprotective anti-hyperglycaemic medications: a review of clinical trials. 2018 , 39, 2368-2375		26
186	Empagliflozin influences blood viscosity and wall shear stress in subjects with type 2 diabetes mellitus compared with incretin-based therapy. <i>Cardiovascular Diabetology</i> , 2018 , 17, 52	8.7	33
185	New Diabetes Therapies and Diabetic Kidney Disease Progression: the Role of SGLT-2 Inhibitors. 2018 , 18, 27		36
184	Paediatric type 2 diabetes in China-Pandemic, progression, and potential solutions. 2018 , 19, 27-35		21
183	No disparity of the efficacy and all-cause mortality between Asian and non-Asian type 2 diabetes patients with sodium-glucose cotransporter 2 inhibitors treatment: A meta-analysis. 2018 , 9, 850-861		31
182	Switching from low-dose thiazide diuretics to sodium-glucose cotransporter 2 inhibitor improves various metabolic parameters without affecting blood pressure in patients with type 2 diabetes and hypertension. 2018 , 9, 875-881		9
181	Clinical potential relevance of metabolic properties of SGLT2 inhibitors in patients with heart failure. 2018 , 14, 1273-1285		4
180	Diabetic Cardiomyopathy: Current and Future Therapies. Beyond Glycemic Control. 2018 , 9, 1514		80
179	Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus. 2018 , 70, 915-921		3
178	Clinical potential of canagliflozin in cardiovascular risk reduction in patients with type 2 diabetes. 2018 , 14, 419-428		6
177	Sodium-glucose Cotransporter 2 Inhibitors: Nephroprotective Impact on Diabetic Kidney Disease. 2018 , 18, 120-126		2
176	Prevention of Heart Failure in Patients with Diabetes: Role of Diabetes Medications. 2018 , 20, 112		4

175	The Changing Landscape of Diabetes Therapy for Cardiovascular Risk Reduction: JACC State-of-the-Art Review. 2018 , 72, 1856-1869		43
174	The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study. 2018 , 11, 749-761		120
173	Sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes in North India: A 12-month prospective study in real-world setting. 2018 , 72, e13237		6
172	Comparative efficacy of once-weekly semaglutide and SGLT-2 inhibitors in type 2 diabetic patients inadequately controlled with metformin monotherapy: a systematic literature review and network meta-analysis. 2018 , 34, 1595-1603		19
171	Systematic review and meta-analysis of the effect of SGLT-2 inhibitors on microvascular outcomes in patients with type 2 diabetes: a review protocol. 2018 , 8, e020692		3
170	SGLT2 inhibition and kidney protection. 2018 , 132, 1329-1339		75
169	The Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Sympathetic Nervous Activity. 2018 , 9, 421		53
168	Cardiac and Renal Effects of Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetes: JACC State-of-the-Art Review. 2018 , 72, 1845-1855		121
167	Hypertension and Diabetes. 2018 , 1-22		
166	SGLT2 inhibition in a kidney with reduced nephron number: modeling and analysis of solute transport and metabolism. <i>American Journal of Physiology - Renal Physiology</i> , 2018 , 314, F969-F984	4.3	52
165	Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: a real-world nationwide population-based cohort study. <i>Cardiovascular Diabetology</i> , 2018 , 17, 91	8.7	31
164	Potential mechanisms responsible for cardioprotective effects of sodium-glucose co-transporter 2 inhibitors. <i>Cardiovascular Diabetology</i> , 2018 , 17, 101	8.7	77
163	Sodium-Glucose Transporter Inhibitors and Diabetic Nephropathy in Humans and Animal Model. 2018 , 03,		1
162	Diabetes Mellitus. 2018 , 341-352		
161	Effect of sodium glucose cotransporter 2 inhibitors on obstructive sleep apnea in patients with type 2 diabetes. 2018 , 65, 461-467		19
160	SGLT2 Inhibition for the Prevention and Treatment of Diabetic Kidney Disease: A Review. 2018 , 72, 267-277		60
159	Are Sodium-Glucose Cotransporter 2 Inhibitors Really Useful and Safe for Advanced Heart Failure?. 2018 , 82, 1752-1753		1
158	SGLT2 inhibitors and the kidney: Effects and mechanisms. 2018 , 12, 1117-1123		26

157	Cardiovascular outcomes of sodium glucose cotransporter-2 inhibitors in patients with type 2 diabetes. 2019 , 21, 28-36		38
156	Cardiometabolic effects of antidiabetic drugs in non-alcoholic fatty liver disease. 2019 , 39, 122-127		1
155	SGLT-2 Inhibitors and Peripheral Artery Disease: A Statistical Hoax or Reality?. 2019 , 44, 207-222		10
154	Empagliflozin attenuates diabetic tubulopathy by improving mitochondrial fragmentation and autophagy. <i>American Journal of Physiology - Renal Physiology</i> , 2019 , 317, F767-F780	4.3	61
153	Sodium-glucose Cotransporter 2 Inhibitors in Heart Failure: Potential Mechanisms of Action, Adverse Effects and Future Developments. 2019 , 14, 23-32		30
152	Effects of the SGLT2 inhibitor dapagliflozin on cardiac function evaluated by impedance cardiography in patients with type 2 diabetes. Secondary analysis of a randomized placebo-controlled trial. <i>Cardiovascular Diabetology</i> , 2019 , 18, 106	8.7	16
151	SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects. 2019 , 16,		76
150	Natural products with SGLT2 inhibitory activity: Possibilities of application for the treatment of diabetes. 2019 , 33, 2518-2530		16
149	Sodium-Glucose Cotransporter-2 Inhibitors, Reverse J-Curve Pattern, and Mortality in Heart Failure. 2019 , 15, 519-530		0
148	Effect of Empagliflozin on Cardiac Function, Adiposity, and Diffuse Fibrosis in Patients with Type 2 Diabetes Mellitus. 2019 , 9, 15348		18
147	Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. 2019 , 9, 13009		29
146	Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Across the Spectrum of Hypertension. 2020 , 33, 207-213		10
145	Renal glucosuria is associated with lower body weight and lower rates of elevated systolic blood pressure: results of a nationwide cross-sectional study of 2.5 million adolescents. <i>Cardiovascular Diabetology</i> , 2019 , 18, 124	8.7	10
144	Sodium-Glucose Cotransporter 2 Inhibition and Diabetic Kidney Disease. 2019 , 68, 248-257		52
143	Dapagliflozin Attenuates Cardiac Remodeling in Mice Model of Cardiac Pressure Overload. 2019 , 32, 452-459		27
142	Effect of SGLT2 Inhibitors on the Sympathetic Nervous System and Blood Pressure. 2019 , 21, 70		41
141	Safety and efficacy of antihyperglycaemic agents in diabetic kidney disease. 2019 , 2, e00072		1
140	Empagliflozin improves primary haemodynamic parameters and attenuates the development of atherosclerosis in high fat diet fed APOE knockout mice. 2019 , 494, 110487		24

139	Promise, peril, and possible new treatment options incurred by sodium glucose co-transporter 2 (SGLT2) inhibitors: A precise review up to 2018. 2019 , 14, 100099		
138	Clinical comparison of tofogliflozin and empagliflozin based on an analysis of 24-h accumulated urine in Japanese patients with type 2 diabetes mellitus. 2019 , 14, 100088		1
137	An evaluation of the efficacy and safety of Tofogliflozin for the treatment of type II diabetes. 2019 , 20, 781-790		4
136	Prise de position de la Société Francophone du Diabète (SFD) : Évaluation du rapport bénéfices-risques des inhibiteurs de SGLT2. 2019 , 13, 195-209		4
135	An update on the safety of SGLT2 inhibitors. 2019 , 18, 295-311		69
134	Blood Pressure Lowering and Sodium-Glucose Co-transporter 2 Inhibitors (SGLT2is): More Than Osmotic Diuresis. <i>Current Hypertension Reports</i> , 2019 , 21, 12	4-7	33
133	Canagliflozin review - safety and efficacy profile in patients with T2DM. 2019 , 12, 209-215		21
132	SGLT2 Inhibitors Therapy in Type 2 Diabetes Mellitus. 2019 ,		1
131	Comparative efficacy of once-weekly semaglutide versus SGLT-2 inhibitors in patients inadequately controlled with one to two oral antidiabetic drugs: a systematic literature review and network meta-analysis. 2019 , 9, e023458		6
130	Searching for optimal blood pressure targets in type 2 diabetic patients with coronary artery disease. <i>Cardiovascular Diabetology</i> , 2019 , 18, 160	8.7	7
129	Effect of sodium glucose cotransporter 2 inhibitors on cardiac function and cardiovascular outcome: a systematic review. 2019 , 17, 26		12
128	Long-Term Effectiveness and Safety of SGLT-2 Inhibitors in an Italian Cohort of Patients with Type 2 Diabetes Mellitus. 2019 , 2019, 3971060		22
127	Efficacy and safety of dapagliflozin as monotherapy in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials. 2019 , 98, e16575		11
126	Effect of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on cisplatin-induced nephrotoxicity in mice. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2019 , 392, 45-53	3-4	15
125	Canagliflozin and Stroke in Type 2 Diabetes Mellitus. 2019 , 50, 396-404		32
124	Renal effects of sodium glucose co-transporter 2 inhibitors in Japanese type 2 diabetes mellitus patients with home blood pressure monitoring. 2019 , 41, 637-644		3
123	First-dose effect of the SGLT2 inhibitor ipragliflozin on cardiovascular activity in spontaneously diabetic Torii fatty rats. 2019 , 46, 266-273		3
122	Unraveling reno-protective effects of SGLT2 inhibition in human proximal tubular cells. <i>American Journal of Physiology - Renal Physiology</i> , 2019 , 316, F449-F462	4-3	23

121	Cardiovascular, renal and liver protection with novel antidiabetic agents beyond blood glucose lowering in type 2 diabetes: consensus article from the European Society of Hypertension Working Group on Obesity, Diabetes and the High-risk Patient. 2020 , 38, 377-386	3
120	Pretreatment with KGA-2727, a selective SGLT1 inhibitor, is protective against myocardial infarction-induced ventricular remodeling and heart failure in mice. 2020 , 142, 16-25	20
119	Failure to confirm a sodium-glucose cotransporter 2 inhibitor-induced hematopoietic effect in non-diabetic rats with renal anemia. 2020 , 11, 834-843	2
118	SGLT-2 Inhibitors in Heart Failure and Type-2 Diabetes: Hitting Two Birds with One Stone?. 2020 , 145, 311-320	14
117	Risk of orthostatic hypotension associated with sodium-glucose cotransporter-2 inhibitor treatment: A meta-analysis of randomized controlled trials. 2020 , 17, 1479164120953625	0
116	Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal risk. <i>Cardiovascular Diabetology</i> , 2020 , 19, 196	8.7 14
115	Cardiovascular Safety and Benefits of Noninsulin Antihyperglycemic Drugs for the Treatment of Type 2 Diabetes Mellitus: Part 2. 2020 , 28, 219-235	4
114	Antidiabetic drugs and blood pressure changes. 2020 , 161, 105108	3
113	Effects of switching from a dipeptidyl peptidase-4 inhibitor to luseogliflozin on nocturnal blood pressure in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, blinded endpoint parallel-group comparison study. 2020 , 10, e034883	1
112	Molecular Mechanisms of SGLT2 Inhibitor on Cardiorenal Protection. 2020 , 21,	15
111	New and emerging cardiovascular and antihypertensive drugs. 2020 , 19, 1315-1327	3
110	Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus. 2020 , 16, 556-577	67
109	Dapagliflozin Activates Neurons in the Central Nervous System and Regulates Cardiovascular Activity by Inhibiting SGLT-2 in Mice. 2020 , 13, 2781-2799	12
108	[COVID-19 and cardiovascular and kidney disease: Where are we? Where are we going?]. 2020 , 46 Suppl 1, 78-87	4
107	Beyond the myocardium? SGLT2 inhibitors target peripheral components of reduced oxygen flux in the diabetic patient with heart failure with preserved ejection fraction. 2020 , 1	0
106	Blood pressure control in type 2 diabetes mellitus with arterial hypertension. The important ancillary role of SGLT2-inhibitors and GLP1-receptor agonists. 2020 , 160, 105052	6
105	Effects of an SGLT2 inhibitor on the salt sensitivity of blood pressure and sympathetic nerve activity in a nondiabetic rat model of chronic kidney disease. 2020 , 43, 492-499	16
104	Efficacy of the treatment with dapagliflozin and metformin compared to metformin monotherapy for weight loss in patients with class III obesity: a randomized controlled trial. 2020 , 21, 186	0

103	Efficacy and safety profile of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease. 2020 , 19, 243-256		10
102	Pancreatic safety of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: A systematic review and meta-analysis. 2020 , 29, 161-172		7
101	Sodium-glucose cotransporter 2 inhibitors represent a paradigm shift in the prevention of heart failure in type 2 diabetes patients. 2021 , 12, 6-20		7
100	Tolerability and Efficacy of Ipragliflozin in The Management of Inadequately Controlled Type 2 Diabetes mellitus: A Systematic Review and Meta-analysis. 2021 , 129, 56-72		8
99	Comparative Efficacy of Dual and Single Initiation of Add-On Oral Antihyperglycemic Agents in Type 2 Diabetes Uncontrolled on Metformin Alone: A Systematic Literature Review and Network Meta-Analysis. 2021 , 12, 389-418		2
98	Effect of sotagliflozin as an adjunct to insulin therapy on blood pressure and arterial stiffness in adults with type 1 diabetes: A post hoc pooled analysis of inTandem1 and inTandem2. 2021 , 18, 1479164121995928		1
97	Adverse events associated with sodium glucose co-transporter 2 inhibitors: an overview of quantitative systematic reviews. 2021 , 12, 2042098621989134		14
96	An Academic Clinician's Road Map to Hypertension Genomics: Recent Advances and Future Directions MMXX. 2021 , 77, 284-295		4
95	Mechanisms and Perspectives of Sodium-Glucose Co-transporter 2 Inhibitors in Heart Failure. 2021 , 8, 636152		4
94	Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A protocol for systematic review and meta-analysis. 2021 , 100, e24655		5
93	Sodium-glucose cotransporter 2 inhibitor-induced reduction in the mean arterial pressure improved renal composite outcomes in type 2 diabetes mellitus patients with chronic kidney disease: A propensity score-matched model analysis in Japan. 2021 , 12, 1408-1416		4
92	SGLT2 inhibitors and sleep apnea; how helpful are the medications: A meta-analysis. 2021 , 2, 100084		2
91	SGLT2 Inhibitors as Calorie Restriction Mimetics: Insights on Longevity Pathways and Age-Related Diseases. 2021 , 162,		6
90	Medical management of resistant hypertension: the role of sodium-glucose cotransporter 2 inhibitors (SGLT2i). 2021 , 36, 420-428		1
89	Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis. <i>Cardiovascular Diabetology</i> , 2021 , 20, 100	8.7	20
88	Sodium-glucose transporter inhibition in heart failure: from an unexpected side effect to a novel treatment possibility. 2021 , 175, 108796		2
87	Hypertension in diabetes care: emerging roles of recent hypoglycemic agents. 2021 , 44, 897-905		2
86	Use of Sodium-Glucose Cotransporter-2 Inhibitors in Renal Transplant Patients With Diabetes: A Brief Review of the Current Literature. 2021 ,		1

85	High-dose sodium-glucose co-transporter-2 inhibitors are superior in type 2 diabetes: A meta-analysis of randomized clinical trials. 2021 , 23, 2125-2136		1
84	Recent Advances in Sodium Glucose Cotransporter-2 Inhibitors. 2021 , 22, 113-125		
83	Serum uric acid is associated with incident metabolic syndrome independent of body shape index and body roundness index in healthy individuals. 2021 , 31, 3142-3151		1
82	Effects of SGLT2 inhibitors on stroke and its subtypes in patients with type 2 diabetes: a systematic review and meta-analysis. 2021 , 11, 15364		2
81	The Na/K-ATPase Signaling and SGLT2 Inhibitor-Mediated Cardiorenal Protection: A Crossed Road?. 2021 , 254, 513-529		0
80	Sodium and glucose cotransporter type 2 inhibitors: a new class of drugs for the treatment of diabetic and non-diabetic nephropathy. 2021 , 25, 33-41		1
79	Resistant arterial hypertension: the search of new approaches to antihypertensive drug therapy. 2021 , 27, 309-317		
78	Cardiometabolic and Kidney Protection in Kidney Transplant Recipients with Diabetes: Mechanisms, Clinical Applications, and Summary of Clinical Trials. 2021 ,		2
77	Reno-protective potential of sodium glucose cotransporter-2 (SGLT2) inhibitors: Summary evidence from clinical and real-world data. 2021 , 907, 174320		2
76	A New Hope in Type 2 Diabetes Mellitus Management: Sodium-Glucose Cotransporter 2 Inhibitors. <i>Cureus</i> , 2021 , 13, e18300	1.2	1
75	The diuretic effects of SGLT2 inhibitors: A comprehensive review of their specificities and their role in renal protection. 2021 , 47, 101285		6
74	SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies. 2021 , 172, 105836		2
73	Effects of dapagliflozin on blood pressure variability in patients with prediabetes and prehypertension without pharmacological treatment: a randomized trial. 2020 , 25, 346-350		4
72	Decrease of cardiovascular risk in patients with type 2 diabetes: review of the common strategies and clinical studies. 2018 , 21, 193-205		5
71	Effects of Ipragliflozin on Diabetic Nephropathy and Blood Pressure in Patients With Type 2 Diabetes: An Open-Label Study. 2017 , 9, 154-162		10
70	Long-Term Effects of Ipragliflozin on Diabetic Nephropathy and Blood Pressure in Patients With Type 2 Diabetes: 104-Week Follow-up of an Open-Label Study. 2018 , 10, 679-687		5
69	Effects of Tofogliflozin on Cardiac Function in Elderly Patients With Diabetes Mellitus. 2020 , 12, 165-171		7
68	TYPE 2 DIABETES AND CARDIOVASCULAR COMPLICATIONS: IS IT POSSIBLE TO IMPROVE PROGNOSIS BY GLUCOSE LOWERING THERAPY?. 2018 , 79-91		5

67	In silico Molecular Docking Study to Search New SGLT2 Inhibitor based on Dioxabicyclo[3.2.1] Octane Scaffold. 2020 , 16, 145-154	4
66	[Advantages of therapy with sodium glucose cotransporter type 2 inhibitors in patients with type 2 diabetes mellitus in combination with hyperuricemia and gout]. 2020 , 92, 110-118	5
65	Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation. 2017 , 21, 1-218	31
64	A review of clinical efficacy and safety of canagliflozin 300 mg in the management of patients with type 2 diabetes mellitus. 2017 , 21, 196-209	9
63	Safe and pragmatic use of sodium-glucose co-transporter 2 inhibitors in type 2 diabetes mellitus: South Asian Federation of Endocrine Societies consensus statement. 2017 , 21, 210-230	9
62	Combination therapy in type 2 diabetes mellitus: adding empagliflozin to basal insulin. 2015 , 4, 212288	5
61	Effects of sodium-glucose co-transporter 2 (SGLT2) inhibition on renal function and albuminuria in patients with type 2 diabetes: a systematic review and meta-analysis. 2017 , 5, e3405	19
60	SGLT2 Inhibitors for Treating Diabetes. 2017 , 13-35	
59	Advantages and disadvantages of new therapies. 2016 , 59-82	
58	Sodium-glucose Cotransporter-2 Inhibitors: Moving Beyond the Glycemic Treatment Goal. 2017 , 21, 909-918	
57	Hypertension and Diabetes. 2018 , 109-130	
56	The metabolic model of heart failure: the role of sodium glucose co-transporter-2 (SGLT-2) inhibition. 2018 , 7, 212549	
55	Hypertension and Diabetes. 2019 , 1-22	
54	Profil de tolérance des inhibiteurs de SGLT2 : le point en 2020. 2020 , 14, 331-341	
53	Effects of Dapagliflozin Compared with Sitagliptin and Metformin in Drug-Naïve Japanese Patients with Type 2 Diabetes: A 12-Week, Open-Label, Randomized, Active-Controlled Trial. 2021 , 12, 3201-3215	1
52	SGLT 2 Inhibitors; glycemic control, weight loss and safety profile in patients with type 2 Diabetes, at Medicell Institute (MIDEM). 2021 , 37, 87-92	2
51	Hypertension and Diabetes. 2020 , 109-130	
50	Clinical Considerations When Introducing Sodium-Glucose Co-Transporter 2 Inhibition in Patients With Heart Failure. 2019 , 2, 51-59	

49	Gender Differences in Cardiac Function Following Three-Month Administration of Tofogliflozin in Patients With Diabetes Mellitus. 2020 , 12, 530-538		2
48	Pharmacological therapy and cardiovascular risk reduction for type 2 diabetes. 2020 , 66, 1283-1288		
47	Does SGLT2 Inhibition Affect Sympathetic Nerve Activity in Type 2 Diabetes?. 2021 , 53, 75-84		1
46	Harms and benefits of sodium-glucose co-transporter 2 inhibitors. 2020 , 43, 168-171		
45	Crosstalk between Sodium-Glucose Cotransporter Inhibitors and Sodium-Hydrogen Exchanger 1 and 3 in Cardiometabolic Diseases. 2021 , 22,		1
44	Diuretic Agents. 2021 ,		
43	Harms and benefits fo sodium-glucose co-transporter 2 inhibitors. 2020 , 43, 168-171		2
42	Sodium-Glucose Cotransporter 2 Inhibition: Rationale and Mechanisms for Kidney and Cardiovascular Protection in People With and Without Diabetes.. 2021 , 28, 298-308		0
41	Effect of SLGT2 Inhibitors on Patients with Atrial Fibrillation.. 2021 , 14, 20200502		
40	Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism.. <i>Frontiers in Pharmacology</i> , 2022 , 13, 800490	5.6	0
39	Efficacy and Safety of SGLT2 Inhibitors as Adjunctive Treatment in Type 1 Diabetes in a Tertiary Care Center in Saudi Arabia.. 2022 , 12, 10-15		
38	SGLT2 Inhibitors in Type 2 Diabetes Mellitus and Heart Failure-A Concise Review.. <i>Journal of Clinical Medicine</i> , 2022 , 11,	5.1	1
37	Beneficial cardiovascular and remodeling effects of SGLT2 inhibitors: pathophysiologic mechanisms.. 2022 ,		
36	Targeting Features of the Metabolic Syndrome Through Sympatholytic Effects of SGLT2 Inhibition.. <i>Current Hypertension Reports</i> , 2022 , 24, 67	4.7	1
35	The Impact of Novel Anti-Diabetic Medications on CV Outcomes: A New Therapeutic Horizon for Diabetic and Non-Diabetic Cardiac Patients.. <i>Journal of Clinical Medicine</i> , 2022 , 11,	5.1	0
34	Empagliflozin Ameliorates Preeclampsia and Reduces Postpartum Susceptibility to Adriamycin in a Mouse Model Induced by Angiotensin Receptor Agonistic Autoantibodies.. <i>Frontiers in Pharmacology</i> , 2022 , 13, 826792	5.6	1
33	Interaction between sodium-glucose co-transporter 2 and the sympathetic nervous system.. <i>Current Opinion in Nephrology and Hypertension</i> , 2022 , 31, 135-141	3.5	1
32	Baseline Characteristics Associated With Sodium-Glucose Cotransporter Inhibitor Prescriptions in Type 2 Diabetic Patients in Jazan, Saudi Arabia. <i>Cureus</i> , 2022 ,	1.2	0

31	Characteristics and molecular mechanisms through which SGLT2 inhibitors improve metabolic diseases: A mechanism review.. <i>Life Sciences</i> , 2022 , 120543	6.8	2
30	SGLT2 inhibition effect on salt-induced hypertension, RAAS, and sodium transport in Dahl SS rats.. <i>American Journal of Physiology - Renal Physiology</i> , 2022 ,	4.3	0
29	Mechanisms underlying the blood pressure lowering effects of dapagliflozin, exenatide, and their combination in people with type 2 diabetes: a secondary analysis of a randomized trial.. <i>Cardiovascular Diabetology</i> , 2022 , 21, 63	8.7	2
28	Canagliflozin mitigates ferroptosis and ameliorates heart failure in rats with preserved ejection fraction.. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2022 , 1	3.4	3
27	Medical Therapies for Heart Failure in Hypoplastic Left Heart Syndrome. <i>Journal of Cardiovascular Development and Disease</i> , 2022 , 9, 152	4.2	
26	Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial.. <i>Circulation</i> , 2022 ,	16.7	1
25	Acute kidney injury following SGLT2 inhibitors among diabetic patients: a pharmacovigilance study.. <i>International Urology and Nephrology</i> , 2022 ,	2.3	1
24	Putative protective effects of sodium-glucose cotransporter 2 inhibitors on atrial fibrillation through risk factor modulation and off-target actions: potential mechanisms and future directions. <i>Cardiovascular Diabetology</i> , 2022 , 21,	8.7	0
23	Potential role of SGLT2 inhibitors in the management of hypertension. <i>Trends in Cardiovascular Medicine</i> , 2022 ,	6.9	
22	Effect of sodium-glucose cotransporter-2 inhibitors on blood pressure in patients with heart failure: a systematic review and meta-analysis. <i>Cardiovascular Diabetology</i> , 2022 , 21,	8.7	0
21	New Strategies for Volume Control in Patients with Diabetes Mellitus, a Narrative Review. 2022 , 14, 1569		
20	Impact of SGLT2 inhibitors on the kidney in people with type 2 diabetes and severely increased albuminuria. 1-16		0
19	Association of glucose-lowering drugs with incident stroke and transient ischaemic attacks in primary care patients with type 2 diabetes: disease analyzer database.		1
18	Biomolecular Mechanisms of Cardiorenal Protection with Sodium-Glucose Co-Transporter 2 Inhibitors. 2022 , 12, 1349		0
17	Dapagliflozin for heart failure according to body mass index: the DELIVER trial.		1
16	Influence of sodium-glucose Co-transporter 2 inhibitors on clinical and biochemical markers of dehydration during the Holy Ramadan. 2022 , 16, 102606		1
15	SGLT2 Inhibitors in Type 2 Diabetes Mellitus. 2022 , 18, 551-559		0
14	EMPAGLIFLOZIN SAFETY AND EFFICACY IN SOUTH INDIAN POPULATION. 2022 , 22-23		0

- 13 Cardiovascular and renal outcomes with sodium glucose co-transporter 2 inhibitors in patients with type 2 diabetes mellitus: A system review and network meta-analysis. 13, ○
- 12 Disparities in efficacy and safety of sodium-glucose cotransporter 2 inhibitor among patients with different extents of renal dysfunction: A systematic review and meta-analysis of randomized controlled trials. 13, ○
- 11 The anti-hypertensive effects of sodium-glucose cotransporter-2 inhibitors. 1-20 ○
- 10 Renal outcomes with sodium-glucose cotransporters 2 inhibitors. 13, ○
- 9 Orthostatic Hypotension and Diabetes. **2023**, 473-485 ○
- 8 Effect of sodium-glucose cotransporter 2 inhibitors on the rate of decline in kidney function: A systematic review and meta-analysis. ○
- 7 Optimizing antihypertensive therapy in patients with diabetes mellitus. ○
- 6 "Adjuvante" Hochdrucktherapie. **2023**, 23, 40-41 ○
- 5 Usage des gliflozines dans la maladie rénale chronique. **2023**, ○
- 4 Transcription factor c-Maf deletion improves streptozotocin-induced diabetic nephropathy by directly regulating Sglt2 and Glut2. **2023**, 8, ○
- 3 Indikationen von Antidiabetika jenseits der Glukosekontrolle. **2023**, 165, 42-49 ○
- 2 The Role of Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure Management: The Continuing Challenge of Clinical Outcome Endpoints in Heart Failure Trials. **2023**, 15, 1092 ○
- 1 Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors in Cardiovascular Disease and Chronic Kidney Disease. **2023**, 12, 2824 ○